Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$492K Sell
1,359
-419
-24% -$143K 0.16% 141
2026
Q1
$626K Sell
1,778
-17
-0.9% -$6.06K 0.22% 131
2025
Q4
$588K Buy
1,795
+538
+43% +$171K 0.2% 132
2025
Q3
$355K Hold
1,257
– – 0.12% 167
2025
Q2
$351K Buy
1,257
+60
+5% +$17K 0.12% 161
2025
Q1
$373K Buy
1,197
+262
+28% +$77.4K 0.14% 150
2024
Q4
$244K Buy
935
+6
+0.6% +$1.78K 0.09% 177
2024
Q3
$293K Buy
+929
New +$304K 0.1% 170
2023
Q2
$2.58M Buy
11,637
+250
+2% +$58K 0.88% 33
2023
Q1
$2.75M Buy
11,387
+630
+6% +$155K 0.93% 30
2022
Q4
$2.83M Buy
10,757
+1,572
+17% +$421K 0.98% 26
2022
Q3
$2.07M Buy
9,185
+1,228
+15% +$298K 0.85% 32
2022
Q2
$1.94M Buy
7,957
+706
+10% +$173K 0.75% 33
2022
Q1
$1.75M Buy
7,251
+1,611
+29% +$370K 0.63% 41
2021
Q4
$1.27M Buy
5,640
+361
+7% +$76.2K 0.44% 61
2021
Q3
$1.12M Buy
5,279
+879
+20% +$202K 0.43% 61
2021
Q2
$1.07M Buy
4,400
+2,237
+103% +$550K 0.41% 65
2021
Q1
$538K Buy
+2,163
New +$516K 0.23% 96

Other funds holding AMGN

44 Wealth Management's AMGN Position: Q2 2026 in Review

44 Wealth Management reduced its Amgen (AMGN) stake by 24% in Q2 2026, selling an estimated $143K and leaving 1,359 shares worth $492K. The position accounts for 0.16% of the portfolio, ranked #141.

44 Wealth Management first reported a position in AMGN in Q1 2021 and has held it in 18 quarters since. The position peaked at $2.83M in Q4 2022. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • 44 Wealth Management held 1,359 shares of Amgen worth $492K as of Q2 2026.
  • 44 Wealth Management sold 419 Amgen shares in Q2 2026, an estimated $143K.
  • Amgen made up 0.16% of 44 Wealth Management's portfolio in Q2 2026, its #141 holding.
  • 44 Wealth Management first reported a position in Amgen in Q1 2021 and has held it in 18 quarters since.
  • 44 Wealth Management's Amgen position peaked at $2.83M in Q4 2022.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on 44 Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.